Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study
These data demonstrate the clinical potential of Trop-2-directed therapy in managing heavily pretreated patients with advanced HNSCC.
Authors
- J. Thaddeus Beck (ORCID: https://orcid.org/0000-0002-3341-9903)
- Caroline Even (ORCID: https://orcid.org/0000-0002-8493-7444)
- Antonio Jimeno (ORCID: https://orcid.org/0000-0001-8560-0440)
- Ammar Sukari (ORCID: https://orcid.org/0000-0003-1968-0459)
- Joanne Chiu
- Elizabeth Ahern (ORCID: https://orcid.org/0000-0002-2062-5695)
- Jilpa Patel
- Sylvie Zanetta (ORCID: https://orcid.org/0000-0003-2002-0255)
- Sabeen Mekan
- Tia Wu (ORCID: https://orcid.org/0009-0002-4562-1284)
- John Hilton (ORCID: https://orcid.org/0000-0002-6280-8633)
- Loren S. Michel
- Ecaterina E Ileana Dumbrava (ORCID: https://orcid.org/0000-0002-1959-0536)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Ottawa (CA)
- Ottawa Hospital (CA)
- Queen Mary Hospital (CN)
- Monash Medical Centre (AU)
- Institut Gustave Roussy (FR)
- Kettering University (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Centre Georges François Leclerc (FR)
- Highlands Oncology Group (US)
- University of Colorado Cancer Center (US)
- Gilead Sciences (United States) (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Hong Kong (HK)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2523
- Citations
- 14
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 3.96